Intravenous busulfan with thiotepa and cyclophosphamide (TBC) as a conditioning regimen for autologous progenitor cell transplantation (PCT) in patients with multiple myeloma (MM).

被引：0
|
作者：
Anagnostopoulos, A [1 ]
Aleman, A [1 ]
Weber, D [1 ]
Andersson, B [1 ]
Braunschweig, I [1 ]
Claxton, D [1 ]
Donato, M [1 ]
Khouri, I [1 ]
Anderlini, P [1 ]
Korbling, M [1 ]
Gajewski, J [1 ]
Alexanian, R [1 ]
Champlin, R [1 ]
Giralt, S [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1497
引用
下载
收藏
页码：335A / 335A
页数：1
相关论文
共 50 条
  • [21] Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
    (Zhang XH
    中华医学杂志(英文版), 2007, (06) : 463 - 468
  • [22] Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
    Zhang XHHuang XJLiu KYXu LPLiu DHChen HChen YHWang JZHan W and Lu DPInstitute of HematologyPeking University Peoples HospitalBeijing China
    ChineseMedicalJournal, 2007, 120 (06) : 463 - 468
  • [23] Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma
    Zhang Xiao-hui
    Huang Xiao-jun
    Liu Kai-yan
    Xu Lan-ping
    Liu Dai-hong
    Chen Huan
    Chen Yu-hong
    Wang Jing-zhi
    Han Wei
    Lu Dao-pei
    CHINESE MEDICAL JOURNAL, 2007, 120 (06) : 463 - 468
  • [24] Pilot study of Busulfan/Thiotepa as conditioning regimen followed by allografting and post transplantation cyclophosphamide in advanced relapsed myeloma patients
    Wolschke, C.
    Klyuchnikov, E.
    Janson, D.
    Heinzelmann, M.
    Christopeit, M.
    Ayuk, F.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S469 - S469
  • [25] Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment
    Zhou, Shiyuan
    Zhai, Yingying
    Yan, Lingzhi
    Shi, Xiaolan
    Shang, Jingjing
    Wu, Depei
    Fu, Chengcheng
    Jin, Song
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [26] Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (05) : 923 - 929
  • [27] High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)
    Sterrenberg, Danielle
    Stiff, Patrick J.
    Parthasarathy, Mala
    Go, Aileen
    Smith, Scott E.
    Rodriguez, Tulio E.
    BLOOD, 2013, 122 (21)
  • [28] THIOTEPA, BUSULFAN, AND CYCLOPHOSPHAMIDE - A NEW PREPARATIVE REGIMEN FOR AUTOLOGOUS MARROW OR BLOOD STEM-CELL TRANSPLANTATION IN HIGH-RISK MULTIPLE-MYELOMA
    DIMOPOULOS, MA
    ALEXANIAN, R
    PRZEPIORKA, D
    HESTER, J
    ANDERSSON, B
    GIRALT, S
    MEHRA, R
    VANBESIEN, K
    DELASALLE, KB
    READING, C
    DEISSEROTH, AB
    CHAMPLIN, RE
    BLOOD, 1993, 82 (08) : 2324 - 2328
  • [29] Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial
    Blanes, Margarita
    de la Rubia, Javier
    Lahuerta, Juan J.
    Gonzalez, Jose D.
    Ribas, Paz
    Solano, Carlos
    Alegre, Adrian
    Sanz, Miguel A.
    LEUKEMIA & LYMPHOMA, 2009, 50 (02) : 216 - 222
  • [30] Toxicity and early response after single daily dose of intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    de la Rubia, J.
    Lahuerta, J. J.
    Gonzalez, J. D.
    Ribas, P.
    Solano, C.
    Sanz, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 192 - 192
12345